Patents by Inventor Mikeljon Nikolich

Mikeljon Nikolich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immunogenic compositions including rough phenotype host strains and complementation DNA fragments
    Patent number: 7416878
    Abstract: Live attenuated vaccines against brucellosis and infection by other diseases are described. It has been discovered that trans complementation of the Brucella wboA gene can be used to maintain an expression vector in an attenuated Brucella host cell in a vaccinee. Further, heterologous antigens can be expressed using this Brucella platform, thus effecting a multivalent vaccine against Brucella and the disease corresponding to the heterologous antigen.
    Type: Grant
    Filed: December 11, 2003
    Date of Patent: August 26, 2008
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: Mikeljon Nikolich, David Hoover
  • Mutant strains of Brucella melitensis and immunogenic compositions
    Publication number: 20050249755
    Abstract: Live attenuated vaccines against brucellosis are described. New mutant strains of Brucella melitensis have been developed, which are attenuated via deletion of the hfq and/or purEK sites. The purEK deletion site does not include insertion of a kanamycin resistance determinant marker or any other introduced antibiotic resistance marker. The hfq deletion site preferably does not include insertion of a kanamycin resistance determinant marker or any other introduced antibiotic resistance marker.
    Type: Application
    Filed: March 3, 2005
    Publication date: November 10, 2005
    Inventors: Mikeljon Nikolich, David Hoover, R. Roop, Gregory Robertson
  • Immunogenic compositions including rough phenotype Brucella host strains and complementation DNA fragments
    Publication number: 20050142151
    Abstract: Live attenuated vaccines against brucellosis and infection by other diseases are described. It has been discovered that trans complementation of the Brucella wboA gene can be used to maintain an expression vector in an attenuated Brucella host cell in a vaccinee. Further, heterologous antigens can be expressed using this Brucella platform, thus effecting a multivalent vaccine against Brucella and the disease corresponding to the heterologous antigen.
    Type: Application
    Filed: December 11, 2003
    Publication date: June 30, 2005
    Inventors: Mikeljon Nikolich, David Hoover